Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
Infectious Disease
•
Vaccines
•
Shingles vaccination
•
Allergy & Immunology
•
Primary Immunodeficiency
•
Primary Care
Would you advise an immunocompromised patient that developed a dermatomal rash after the first recombinant zoster vaccine to receive the second dose?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
Is there any role for administering another course of recombinant zoster vaccine (Shingrix) in a previously vaccinated patient with RA, who is in clinical remission on JAK inhibitor but has had a breakthrough shingles infection?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Do you recommend lifelong antibiotic prophylaxis, or do you prefer a more selective approach based on risk factors in asplenic patients without a history of severe infections?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
